Mrs. S, age 46, has been struggling to manage depression for 7 years. She completed adequate trials of several selective serotonin reuptake inhibitors and bupropion. Currently, she is taking duloxetine, 60 mg/d, and aripiprazole, 5 mg/d.

At her most recent clinic visit, Mrs. S reports that she is doing “OK,” but that she still feels sad and disengaged most days of the week. She wants to know more about ketamine for treating depression after reading about it on the Internet and hearing it mentioned in a support group she attends. She asks if you think it would work for her, and gives you with a copy of an article about its use in patients with treatment-resistant depression. Mrs. S has no other health conditions and takes a daily vitamin D and calcium supplement.

The monoamine hypothesis of depression postulates that symptoms originate from underactivity of monoamines, such as serotonin, norepinephrine, and dopamine, in the brain. This hypothesis was formulated in the 1960s after researchers observed that monoamine oxidase inhibitors and tricyclic antidepressants relieved depressive symptoms; both were known to increase monoamine concentrations in the synaptic cleft. Most antidepressants act by increasing concentration of ≥1 of these primary monoamines in the neuronal synapse.

Regrettably, these medications do not adequately relieve depressive symptoms for many people. In fact, symptom remission occurs in only one-third of treated patients. This low remission rate reflects a lack of understanding of the pathophysiology of depression, and the need for drugs with unique mechanisms of action.

One of the newest drug targets shown to be relevant in psychiatric illness is the glutamatergic system. Glutamate is the predominant excitatory neurotransmitter in the CNS, and it is responsible for many key functions, including synaptic plasticity, learning, memory, and locomotion. Normally, the glutamatergic system

---

**Practice Points**

- Medications with novel mechanisms of action are needed to help the two-thirds of depressed patients who do not achieve remission with available antidepressants.
- Ketamine has shown potential as a rapid-acting antidepressant. However, because of complications associated with administration, adverse events, and abuse potential, if it is used in the future as an antidepressant it will likely be limited to emergent, inpatient settings.
- New medications that modulate the glutamatergic system are promising for those who do not remit after completing adequate antidepressant trials.
tightly regulates the amount of glutamate in the neuronal synapse via receptors on presynaptic and postsynaptic neurons, as well as on glial cells (Figure). When this equilibrium is disrupted in stressful situations, such as ischemia, trauma, or seizures, excess glutamate is released into the synapse. The resulting glutamatergic hyperactivity can lead to neurotoxicity and cell death when neuronal receptors are activated for an extended period.

A key component of the glutamatergic system that is responsible for removing excess glutamate from the synapse is membrane-bound transporters, which are similar to serotonin and norepinephrine transporters. These excitatory amino acid transporters (EAATs) are important because glutamate metabolism does not occur within the synapse and EAATs are responsible for removing most of the glutamate from the synapse into glial cells.\(^3\)

The network of receptors within the synapse that are activated by glutamate is extensive and complex. There are at least 11 glutamate-responsive receptors: 3 are ionotrophic action channels, and the remaining 8 are metabotropic G protein-coupled receptors. Previous studies have shown regional changes in glutamate receptors, as well as elevated levels of glutamate, in the brains of patients with major depressive disorder (MDD).\(^4\)
Glutamatergic drugs

Ketamine. The ionotropic receptor N-methyl-D-aspartate (NMDA) is one of the most studied glutamate receptors. Pharmacologically, ketamine is a noncompetitive NMDA receptor antagonist that also activates the amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, which is another subtype of ionotropic glutamate receptors. In open-label clinical trials, ketamine has demonstrated rapid antidepressant action in patients with treatment-resistant MDD.4,5

Recently, Murrough et al6 performed the first randomized, psychoactive controlled trial using a single IV infusion of ketamine dosed below anesthesia ranges (0.5 mg/kg), or midazolam (0.045 mg/kg), in patients with treatment-resistant depression who had been antidepressant-free for at least 4 weeks. They found that 24 hours after medication administration, the likelihood of response to ketamine was significantly higher than the response to midazolam (OR: 2.18; 95% CI: 1.21 to 4.14), with a response rate of 64% in the ketamine group and 28% in the midazolam group.6

Psychotropic side effects, such as hallucinations, are a major concern with ketamine tolerability and abuse potential. This is largely because of ketamine’s antagonism of the NMDA receptor, which is a property shared with other abused drugs such as phencyclidine (PCP) and dextromethorphan. In the Murrough et al6 study, there were no reported cases of paranoia or hallucinations, but disso-
A review by Lapidus et al has a more extensive listing of current medications and investigational compounds that modulate glutamate transmission, and are of interest for their possible antidepressant activity. Given the relatively new “glutamatergic hypothesis” of depression, it is exciting that so many current and novel glutamatergic drug therapies are being evaluated.

Future of ketamine treatment
Glutamate has been shown to play an important part in the pathophysiology of depression. The rapid antidepressant efficacy of ketamine provides evidence that future medications with glutamate-modulating activity could be useful for patients who struggle to achieve symptom relief using available antidepressants. Several limitations exist regarding ketamine use, and more work in this important therapeutic area needs to be done. This last point is important to remember when speaking with patients such as Mrs. S. Although it is understandable for her to be excited about novel treatment options such as ketamine, stress to her that treating depression with ketamine at this time is strictly investigational, and that the drug needs to be thoroughly evaluated for safety and efficacy before it can be prescribed for this indication.

CASE CONTINUED
Mrs. S realizes that ketamine may not be the best next step for her, and she agrees to explore other approaches to treat her residual depressive symptoms.

References